7th Annual Symposium:

The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically-predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.

This symposium will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross discipline discussions on current techniques and how to move forward with future approaches.

Register Now

Registration for the event is required. Attendance for the symposium is free and lunch will be served, but spaces are limited. We encourage you to register early. 

Speakers

Gunnar Kauffman Ph.D. Chief Scientific Officer, Oncternal Therapeutics Talk Title: Eye of the Beholder: ROR1 as Ideal Target for Immunotherapies?

Elena Brin Ph.D. Chief Scientific Officer, Athae Bio Talk Title: Combining Direct Cancer Cell Targeting/Killing with TIL Engagement for a Multipronged Approach to Cancer Treatment

Carine Bossard Ph.D. Director, Tumor Biology, Biosplice Therapeutics Talk Title: The Pan-CLK/DYRK Inhibitor Cirtuvivint (SM08502) Selectively Disrupts Alternative Splicing (AS) and Has Broad Anti-tumor Activity in Preclinical Models

James Ernst Ph.D. Executive Director, Head of Protein Sciences & Technology, Head of Development Sciences at Xencor Talk Title: Modulating the Immune System with Bispecific Antibodies and Engineered Cytokines

Shivani Malik Ph.D. Associate Director, Kura Oncology, Inc. Talk Title: Tipifarnib Potentiates the Antitumor Effects of PI3Kα Blockade in HNSCC via Convergent Inhibition of mTOR Activity

Dean Campbell Ph.D. Senior Director, Scientific Engagement, Crown Bioscience Talk Title: Identifying Clinical Candidates with Cancer Organoids

Lars Engstrom Ph.D. Principal Scientist, Mirati Therapeutics Talk Title: Enabling a Parallel Translational Biology Strategy for MRTX1719, a Selective PRMT5•MTA Complex Inhibitor for MTAP/CDKN2A Deleted Cancers